How do placenta-crossing cytokines during maternal immune activation contribute to Neurodevelopmental, Psychiatric, Addiction Disorders as well as other Health Issues across the Lifespan?

Prenatal maternal immune activation (MIA) creates a surge of cytokines that can reach the placenta and fetus, “programming” brain and body systems. This programming shapes risk for neurodevelopmental and psychiatric disorders and may also affect immune, metabolic, and other health outcomes across the lifespan.

Key Placenta-Crossing Cytokines and Fetal Brain Effects

- MIA elevates **IL-6, IL-1β, TNF-α, IL-17A and others**, which cross the placenta and enter fetal circulation. (Tang et al., 2025; Zawadzka et al., 2021)- IL-6 (and some others) also penetrate the **fetal blood–brain barrier**, activating microglia and disrupting neurogenesis, migration, and cortical layering. (Tang et al., 2025)- In rat and mouse models, maternal IL-6 has been shown to cross the placenta and is required to produce long-lasting behavioral abnormalities; blocking IL-6 prevents these effects. (Boulanger-Bertolus et al., 2018)## Placenta as an Immune and Programming Hub
- The placenta can both **transfer maternal cytokines** and produce its own inflammatory mediators, altering nutrient/oxygen delivery and fetal brain cytokine balance. (Osman et al., 2024; Woods et al., 2022)- MIA alters placental cytokines (e.g., increased IL-6, TNF-α, GM-CSF) and transporters, changing amino acid delivery and **fetal brain growth**, which is linked to later NDD risk. (Osman et al., 2024; Kowash et al., 2022)- Placental and fetal brain gene expression after MIA is enriched for **synaptic and neuronal development pathways**, supporting direct programming of circuitry. (Osman et al., 2024)## Links to Neurodevelopmental & Psychiatric Disorders
- Epidemiological and mechanistic work links maternal inflammatory states (infection, obesity, asthma, autoimmune disease, stress) to **ASD, ADHD, Tourette syndrome, schizophrenia and other NDDs** via placental/BBB cytokine signaling and microglial priming. (Han et al., 2021; Gumusoglu & Stevens, 2019)- Reviews emphasize that cytokine-driven microglial activation, oxidative stress and mitochondrial dysfunction in the fetal brain can produce **ASD-like and schizophrenia-like phenotypes**. (Zawadzka et al., 2021; Otero & Antonson, 2022)## Broader Lifespan Health Consequences
- MIA “fetal programming” affects not only the brain but also the **offspring immune system**, with lasting alterations in cytokine profiles and immune cell function and possible links to allergies and asthma. (Hofsink et al., 2024; Jradi et al., 2026)- Reviews of placental inflammation and maternal obesity highlight associations with **metabolic diseases, atopy, and malignancies** later in life, likely mediated by altered cytokine and immune environments in utero. (Goldstein et al., 2020; Denizli et al., 2022)## Addiction and Psychiatric Vulnerability

The provided papers primarily link MIA-related cytokines to neurodevelopmental and psychiatric disorders; some reviews suggest that these early neuroimmune and microglial changes broadly increase **psychiatric risk**, which can include vulnerability to later substance-related problems, though specific addiction pathways are not detailed here. (Gumusoglu & Stevens, 2019)## Conclusion

Placenta-crossing cytokines during maternal immune activation reshape placental function, fetal brain development, and the developing immune system. This neuroimmune programming raises risk for neurodevelopmental and psychiatric disorders and is linked to broader immune, respiratory, and metabolic problems across the lifespan.

References

Boulanger-Bertolus, J., Pancaro, C., & Mashour, G. (2018). Increasing Role of Maternal Immune Activation in Neurodevelopmental Disorders. *Frontiers in Behavioral Neuroscience, 12*. https://doi.org/10.3389/fnbeh.2018.00230

Denizli, M., Capitano, M., & Kua, K. (2022). Maternal obesity and the impact of associated early-life inflammation on long-term health of offspring. *Frontiers in Cellular and Infection Microbiology, 12*. https://doi.org/10.3389/fcimb.2022.940937

Goldstein, J., Gallagher, K., Beck, C., Kumar, R., & Gernand, A. D. (2020). Maternal-Fetal Inflammation in the Placenta and the Developmental Origins of Health and Disease. *Frontiers in Immunology, 11*. https://doi.org/10.3389/fimmu.2020.531543

Gumusoglu, S., & Stevens, H. (2019). Maternal Inflammation and Neurodevelopmental Programming: A Review of Preclinical Outcomes and Implications for Translational Psychiatry.. *Biological psychiatry, 85 2*, 107-121. https://doi.org/10.1016/j.biopsych.2018.08.008

Han, V., Patel, S., Jones, H., & Dale, R. (2021). Maternal immune activation and neuroinflammation in human neurodevelopmental disorders. *Nature Reviews Neurology, 17*, 564 - 579. https://doi.org/10.1038/s41582-021-00530-8

Han, V., Patel, S., Jones, H., Nielsen, T. C., Mohammad, S., Hofer, M., Gold, W., Brilot, F., Lain, S., Nassar, N., & Dale, R. (2021). Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. *Translational Psychiatry, 11*. https://doi.org/10.1038/s41398-021-01198-w

Hofsink, N., Groenink, L., & Plösch, T. (2024). The fetal programming effect of maternal immune activation (MIA) on the offspring's immune system. *Seminars in Immunopathology, 46*. https://doi.org/10.1007/s00281-024-01023-8

Jradi, W., Duhm, K., & Da Costa, C. P. (2026). Developmental Impact of Maternal Immune Activation on the Fetal Immune System and Lung. *European Journal of Immunology, 56*. https://doi.org/10.1002/eji.70138

Kowash, H. M., Potter, H. G., Woods, R., Ashton, N., Hager, R., Neill, J., & Glazier, J. (2022). Maternal immune activation in rats induces dysfunction of placental leucine transport and alters fetal brain growth. *Clinical Science (London, England : 1979), 136*, 1117 - 1137. https://doi.org/10.1042/cs20220245

Osman, H. C., Moreno, R. J., Rose, D. R., Rowland, M., Ciernia, A., & Ashwood, P. (2024). Impact of maternal immune activation and sex on placental and fetal brain cytokine and gene expression profiles in a preclinical model of neurodevelopmental disorders. *Journal of Neuroinflammation, 21*. https://doi.org/10.1186/s12974-024-03106-7

Otero, A., & Antonson, A. M. (2022). At the crux of maternal immune activation: Viruses, microglia, microbes, and IL-17A. *Immunological Reviews, 311*, 205 - 223. https://doi.org/10.1111/imr.13125

Tang, Q., Wang, X., Yang, F., Liang, L., Li, Y., Liu, W., Zhou, R., & B. (2025). Pathophysiological associations between maternal immune activation and neurodevelopmental disorders in offspring: a comprehensive review. *Frontiers in Endocrinology, 16*. https://doi.org/10.3389/fendo.2025.1681190

Woods, R., Lorusso, J. M., Fletcher, J., ElTaher, H., McEwan, F., Harris, I., Kowash, H. M., D'Souza, S., Harte, M. K., Hager, R., & Glazier, J. (2022). Maternal immune activation and role of placenta in the prenatal programming of neurodevelopmental disorders. *Neuronal Signaling, 7*. https://doi.org/10.1042/ns20220064

Zawadzka, A., Cieślik, M., & Adamczyk, A. (2021). The Role of Maternal Immune Activation in the Pathogenesis of Autism: A Review of the Evidence, Proposed Mechanisms and Implications for Treatment. *International Journal of Molecular Sciences, 22*. https://doi.org/10.3390/ijms222111516